The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer

Cancer Chemotherapy and Pharmacology
Koki GotoItaru Endo

Abstract

To assess the predictive ability of the maximum chemiluminescence intensity (CImax) for severe neutropenia (SN) during neoadjuvant chemo(radio)therapy [NAC(RT)] in patients with advanced pancreatic or biliary tract cancer. Clinicopathological variables and blood test data before NAC(RT) were evaluated in 64 patients with advanced pancreatic or biliary tract cancer who received gemcitabine plus tegafur/gimeracil/oteracil as NAC(RT). Thirty-nine patients (60.9%) developed Grade 3-4 SN. The median time between commencing NAC(RT) and the onset of SN was 15 (range 10-36) days. SN occurred during the NAC period, not the RT period. The CImax, neutrophil count, serum interleukin-6 level, C-reactive protein level, complement C3 titer, serum complement titer, and 50.0% hemolytic unit of complement before NAC(RT) were significantly lower in patients with SN than in those without SN (P < 0.05). Multivariate analysis confirmed the CImax to be the sole independent predictor of SN (P < 0.05). The optimal threshold for the CImax was 46,000 RLU/s. The sensitivity and specificity were 46.2% and 80.0%, respectively. Majority of the patients (81.8%) with a low CImax before NAC(RT) experienced SN during NAC(RT). CImax before NAC(RT) predicts SN dur...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AlexandreF Goldwasser
Dec 20, 2002·Nature·Lisa M Coussens, Zena Werb
Nov 13, 2003·British Journal of Cancer·D A CameronR C F Leonard
May 27, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A G PallisUNKNOWN Hellenic Oncology Research Group (HORG)
Jan 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MoreauM Paesmans
Feb 17, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kohei ShitaraKei Muro
May 22, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KanaiM Fukushima
Apr 17, 2012·Journal of the American Academy of Dermatology·Alice P ChenMario E Lacouture
May 9, 2012·Cancer Chemotherapy and Pharmacology·Toshitaka UchiyamaKayoko Saito
Nov 13, 2012·Journal of Cancer Research and Clinical Oncology·Nelson L S TangWinnie Yeo
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideki UenoMasao Tanaka
Oct 2, 2013·Oncology·Meaghan O'MalleyNithya Ramnath
Jul 11, 2014·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Mihoko SugishitaYuichi Ando
Nov 13, 2015·Cancer Chemotherapy and Pharmacology·Tatsuya KuriharaYuji Kiuchi
Jan 20, 2017·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·S KobayashiM Sakon

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

Statistical Package for the Social Sciences
SPSS

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

The New England Journal of Medicine
Andrea Cariati
The New England Journal of Medicine
Ferris M Hall
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert R McWilliams, Steven R Alberts
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
T Brunner
© 2022 Meta ULC. All rights reserved